Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05950464 · ClinicalTrials.gov registry record · Phase 1
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
A Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Platinum-Resistant Ovarian Carcinoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 14
- Study locations
NCT05950464 is a Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Platinum-Resistant Ovarian Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants, below the 249-participant average among 19 other Recurrent Endometrial Carcinoma trials with a reported enrollment target (76% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT05950464, a Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Platinum-Resistant Ovarian Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- DRUG BET Bromodomain Inhibitor ZEN-3694
- PROCEDURE Electrocardiography
Study Locations (14)
Ohio
- Case Western Reserve University - Cleveland
- Cleveland Clinic Foundation - Cleveland
- Ohio State University Comprehensive Cancer Center - Columbus
Pennsylvania
- NRG Oncology - Philadelphia
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
- Thomas Jefferson University Hospital - Philadelphia
Georgia
- Augusta University Medical Center - Augusta
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
New Mexico
- University of New Mexico Cancer Center - Albuquerque
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05950464
The ClinicalTrials.gov registry entry for NCT05950464 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 249-participant average among 19 other Recurrent Endometrial Carcinoma trials with a reported enrollment target (76% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Recurrent Endometrial Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05950464 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Ohio, Pennsylvania, Georgia.
Frequently Asked Questions
What is clinical trial NCT05950464 about?
NCT05950464 is a clinical study titled "Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer". This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M...
What is the current status of trial NCT05950464?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-12-18. Estimated completion is 2026-04-30.
What conditions does trial NCT05950464 study?
This clinical trial studies the following conditions: Recurrent Endometrial Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma.
What interventions are being tested in trial NCT05950464?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), BET Bromodomain Inhibitor ZEN-3694 (DRUG), Electrocardiography (PROCEDURE).
Who is sponsoring clinical trial NCT05950464?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05950464 being conducted?
This trial has 14 study locations across Georgia, Illinois, Iowa, Michigan, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
RECRUITING · Phase 1
-
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
RECRUITING · Phase 1
-
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Endometrial Carcinoma
All registered trials for this condition
Recurrent Platinum-Resistant Ovarian Carcinoma
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.